Kết quả của việc ghép gan sử dụng các mảnh ghép gan dương tính với kháng thể viêm gan B: Những tác động đối với biện pháp phòng ngừa

Chung RT, Feng S, Delmonico FL: Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1:185–191. Important paper addressing current state of evaluation, treatment, and surveillance of the allograft recipients exposed to hepatitis B. Dodson SF, Issa S, Araya V, et al.: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997, 64:1582–1584. Douglas DD, Rakela J, Taswell HF, et al.: Transmission of hepatitis B virus (HBV) infection from orthotopic donor livers [abstract]. Hepatology 1992, 16:49A. Chazouilleres O, Mamish D, Kim M, et al.: "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994, 343:142–146. Wachs ME, Amend WJ, Ascher NL, et al.: The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59:230–234. Uemoto S, Sugiyama K, Marusawa H, et al.: Transmission of hepatitis B virus from hepatitis B core antibodypositive donors in living related liver transplants. Transplantation 1998, 65:494–499. Prieto M, Gomez MD, Berenguer M, et al.: De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51–58. Douglas DD, Rakela J, Wright TL, et al.: The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997, 3:105–111. Manzarbeitia C, Reich DJ, Ortiz JA, et al.: Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8:556–561. Demonstrated safety of using hepatitis B core antibody (HBcAb)-positive liver grafts. Roque-Afonso AM, Feray C, Samuel D, et al.: Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002, 50:95–99. Yu AS, Vierling JM, Colquhoun SD, et al.: Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001, 7:513–517. Chen YS, Wang CC, de Villa VH, et al.: Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002, 16:405–409. Lee KH, Wai CT, Lim SG, et al.: Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001, 7:469–470. Berner J, Kadian M, Post J, et al.: Prophylactic recombinant hepatitis B vaccine in patients undergoing orthotopic liver transplantation. Transplant Proc 1993, 25:1751–1752. Segovia R, Sanchez-Fueyo A, Rimola A, et al.: Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001, 7:106–112. Crippin J, Foster B, Carlen S, et al.: Retransplantation in hepatitis B: a multicenter experience. Transplantation 1994, 57:823–826. Tipples GA, Ma MM, Fischer KP, et al.: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24:714–717. O’Grady JG, Smith HM, Davies SE, et al.: Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104–111. Terrault NA, Zhou S, Combs C, et al.: Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 24:1327–1333. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ: Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978, 298:1379–1383. de Villa VH, Chen YS, Chen CL: Hepatitis B core antibodypositive grafts: recipient’s risk. Transplantation 2003, 75:S49-S53. Douglas DD, Rakela J, Taswell HF, et al.: Hepatitis B virus replication patterns after orthotopic liver transplantation: de novo versus recurrent infection. Transplant Proc 1993, 25:1755–1757. Aldersley MA, Eglin RE, O’Grady JG: Liver transplantation and de novo hepatitis B infection. Lancet 1994, 343:677. Dodson SF, Bonham CA, Geller DA, et al.: Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999, 68:1058–1061. Bartholomew MM, Jansen RW, Jeffers LJ, et al.: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997, 349:20–22. Schiff ER, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419–1427. Burton JR Jr, Shaw-Stiffel TA: Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003, 9:837–842. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al.: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14–18. Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999, 30:770–774. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al.: Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 1996, 28:17–20. Jilg W, Hottentrager B, Weinberger K, et al.: Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001, 63:96–102. Saab S, Chang AJ, Comulada S, et al.: Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003, 9:1053–1061. Demonstrates that HBc-positive grafts can be used in non-hepatitis B-infected individuals. Bárcena R, Domínguez-Antonaya, López-Sanromán A, et al.: Lamivudine therapy of hepatitis B virus-related liver disease: cirrhosis, post-transplantation recurrence, and de novo infection. Transplant Proc 1999, 31:2457–2458. Joya-Vazquez PP, Dodson FS, Dvorchik I, et al.: Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002, 73:1598–1602. Anselmo DM, Ghobrial RM, Jung LC, et al.: New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002, 235:611–619. Katsurada A, Marusawa H, Uemoto S, et al.: Circulating antibody to hepatitis B core antigen does not always reflect the latent hepatitis B virus infection in the liver tissue. Hepatol Res 2003, 25:105–114. Lo CM, Fan ST, Liu CL, et al.: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003, 9:827–832. Rokuhara A, Tanaka A, Yagi S, et al.: De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000, 62:471–478. Fontana RJ, Merion RM: Are we ready for marginal hepatitis B core antibody-positive living liver donors? Liver Transpl 2003, 9:833–836. Excellent review on clinical implications of using HBcAb-positive living liver donors. Gallegos-Orozco J, Vargas H, Rakela J: Virologically compromised donor grafts in liver transplantation. Hepatology 2004, 41:512–521. Vargas HE, Dodson FS, Rakela J: A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl 2002, 8:2–9. Castells L, Esteban R: Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001, 13:359–361. Domínguez M, Bárcena R, García M, et al.: Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000, 6:440–442. Perrillo RP, Wright T, Rakela J, et al.: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 3:424–432. Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673. Holt D, Thomas R, Van Thiel D, Brems JJ: Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002, 137:572–575. Loss GE, Mason AL, Blazek J, et al.: Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001, 156:55–58. Fabrega E, Garcia-Suarez C, Guerra A, et al.: Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003, 9:916–920. Nery JR, Nery-Avila C, Reddy KR, et al.: Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75:1179–1186.